Organon & (US:OGN) Prnewswireยท2025-06-09 09:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][2]. Allegations - The complaint alleges that Organon's management provided overly positive statements while concealing the prioritization of debt reduction following the acquisition of Dermavant, which led to a significant reduction in the quarterly dividend by 70% [1]. - Following the announcement of the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from October 31, 2024, to April 30, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for July 22, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, with no cost or obligation to participate [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices, aiming to ensure companies adhere to responsible business practices [3].